Defilade Capital Management

Defilade Capital Management as of March 31, 2026

Portfolio Holdings for Defilade Capital Management

Defilade Capital Management holds 31 positions in its portfolio as reported in the March 2026 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
Zimmer Holdings (ZBH) 7.4 $52M 579k 90.42
Henry Schein (HSIC) 6.5 $46M 624k 73.70
Becton, Dickinson and (BDX) 6.2 $44M 279k 157.23
Pfizer (PFE) 5.8 $41M 1.5M 28.08
Dex (DXCM) 4.8 $34M 539k 62.80
ICU Medical, Incorporated (ICUI) 4.6 $33M 254k 129.15
Insmed Com Par $.01 (INSM) 4.5 $32M 195k 163.52
Intuitive Surgical Com New (ISRG) 4.4 $31M 68k 460.99
Revolution Medicines (RVMD) 4.3 $31M 316k 97.25
Globus Med Cl A (GMED) 4.3 $31M 354k 86.16
Neurocrine Biosciences (NBIX) 3.9 $28M 210k 131.74
Denali Therapeutics (DNLI) 3.7 $26M 1.4M 19.20
Ptc Therapeutics I (PTCT) 3.6 $26M 376k 68.13
Olema Pharmaceuticals (OLMA) 3.1 $22M 1.5M 14.91
Elanco Animal Health (ELAN) 3.1 $22M 931k 23.93
Pacs Group Com Shs (PACS) 2.7 $19M 604k 32.12
Eli Lilly & Co. (LLY) 2.7 $19M 21k 919.77
Lantheus Holdings Inc Common Stock Usd 0.01 (LNTH) 2.7 $19M 249k 75.85
Integer Hldgs (ITGR) 2.6 $19M 213k 88.00
Biogen Idec (BIIB) 2.5 $18M 96k 183.33
Evommune Com Shs (EVMN) 2.2 $16M 679k 22.99
Tandem Diabetes Care Com New (TNDM) 2.1 $15M 762k 19.17
Cogent Biosciences (COGT) 1.9 $14M 353k 38.49
Nuvalent Inc-a (NUVL) 1.9 $13M 130k 102.45
Ocular Therapeutix (OCUL) 1.8 $13M 1.5M 8.47
Ascendis Pharma A/s Sponsored Adr (ASND) 1.7 $12M 52k 228.73
Align Technology (ALGN) 1.6 $12M 67k 171.43
Eledon Pharmaceuticals (ELDN) 1.5 $11M 3.6M 3.08
Oric Pharmaceuticals (ORIC) 1.5 $11M 843k 12.67
Biohaven (BHVN) 0.4 $2.7M 316k 8.46
Mereo Biopharma Group Spon Ads (MREO) 0.4 $2.5M 7.6M 0.33